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Of the 200,000 brain tumors diagnosed in the United States each year, approximately 
23% of them are glioblastomas (Brain Tumor Society 2004). These aggressive tumors 
spread rapidly and are resistant to standard treatment, and the average survival rate of 
patients diagnosed with glioblastomas is approximately one year. Current research 
suggests there is great potential for neural stem cells (NSCs) to be used as a delivery 
vehicle for therapeutic agents against tumors. Studies have shown NSCs have an 
innate attraction to tumors and other inflammatory diseases of the brain. This NSC 
pathotropism is due in part to inflammatory signals, angiogenesis, reactive astrocytosis, 
and tumor cytokines (M&uumlller, et al. 2006). By harnessing their natural tropism, 
NSCs engineered with chemotherapeutic properties can be used to track and target 
tumors for destruction. To demonstrate the therapeutic potential of NSCs as a 
transplantable, therapeutic delivery system, we are investigating the in vivo migratory 
behavior and cellular fate of neuralized mouse embryonic stem cells (mESCs) in the 
presence of glioma cells. In this study, neuralized mESCs and SF767 human 
glioblastoma cells were injected into opposite hemispheres of the mouse cortex, and 
frozen sections of the brain tissue were examined to determine the extent of mESC 
migration and survival. After 3 days in vivo, co-localization of tumor and neuralized 
mESCs was evident in multiple sections. Previously, we have seen co-localization of 
neuralized mESCs and tumor cells on organotypic mouse brain slices after 
approximately one week of migration. NSC migration to tumor cells in vivo lends support 
to current efforts to use stem cells as a therapeutic deliver system. Furthermore, the 
neuralized mESCs' proximity to the tumor cells will allow for the specific delivery of 
chemotherapeutic agents to tumor sites. Expanding our knowledge of fundamental 
characteristics and behaviors of neural stem cells will facilitate the development of novel 
and effective stem cell therapies for glioblastomas.  
 
